{‘She possesses zero experience’: the US medical establishment girds for Høeg's tenure at the FDA.

While America continues making unprecedented revisions to its vaccination guidelines, one figure has emerged unexpectedly: Høeg, a US-based sports physician and epidemiologist who first made her name by questioning Covid vaccines throughout the global health crisis and has zeroed in on potential deaths after COVID-19 immunization in her recent time at the FDA.

Proposed Overhauls to Pediatric Vaccine Schedule

Agency leaders were set to announce major revisions to the childhood vaccine schedule in December, synchronizing the US with the Danish national calendar, sources say – a significant shift that would put the US out of step with much of the global community with no evidence for benefit. The announcement has been delayed until the coming year.

In place of the director of the vaccine center, Høeg is set to speak at the gathering. She was just designated temporary leader of the FDA’s CDER, the fifth appointee to run the center this year.

A Shift at the Agency

This interim role may indicate a strengthened alliance between the pharmaceutical and biologics divisions as Høeg and Prasad consolidate power at the regulatory agency – and it points to a greater focus upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has frequently advocated for discontinuing some pediatric vaccine recommendations in the US in order to be more in line with Denmark's approach, a nation with nationalized medicine and a number of inhabitants roughly the population of Wisconsin’s.

So far statements, she has continued to focus on vaccination policy – usually the responsibility of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Concerns Over Expertise

Høeg has little discernible track record in pharmaceutical research, approval processes or administrative roles, which has been standard for former leaders of the biologics center. She has served at the FDA as a senior adviser to the FDA chief and CBER since spring.

“It seems she lacks to have any of the qualifications” for overseeing the drug-regulation department, said Dr. Jonathan Howard. “She has not conducted a clinical trial. She is not versed in leading a major agency. She lacks background in drug approvals.”

Past heads of the center would “grasp laws and regulations and the research of drug development”, noted Janet Woodcock. “Frankly, she doesn’t have the type of experience that former directors who ran CBER have had.”

The drug center has an immense range of responsibilities at the FDA, Woodcock stated.

“Many people just pays attention on the innovative therapies, but the generic drug division authorizes thousands of generic medications. There is also a biologic copycat branch, over-the-counter program and other areas, and each of these have to be supervised,” Dr. Woodcock said. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

There is also, a major administrative component to the position, which oversees over 5,000 staff members. “It is a massive management job, if you execute it properly,” she said.

Agency Reaction and Contentious Policies

When asked about questions about Dr. Høeg's qualifications and whether this appointment represents greater collaboration among agency officials on vaccines, a press secretary stated that the “questions stem from incorrect presumptions”.

“Her experience matches the responsibilities of her job,” the spokesperson said, citing the time Høeg spent counseling the FDA commissioner on “medication safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Høeg takes over the agency head's controversial expedited review system, a disputed expedited drug-approval program that allegedly troubled her former heads. “By what process are these drugs being picked for this voucher program? Who is making the choices?” Howard said. “There is a lot of confidentiality going on at the FDA right now.”

Broadly speaking, he stated, “the FDA seems to be moving towards less stringent regulations of all drugs, aside from vaccines.”

Public History on Vaccines

Regarding vaccines, Høeg has a clearer, if troubling, history, Howard observe. She authored a research paper using unconfirmed crowd-sourced reports to estimate the incidence of heart inflammation following Covid vaccination. She consulted for the state of Florida chief medical officer Joseph Ladapo, who reportedly have changed statistics to imply COVID-19 vaccinations are riskier than they are.

Included in her “wish list” for the current administration encompassed changing rules for novel immunizations and discontinuing “optional” vaccines, she remarked after the election on a podcast. At the agency, Dr. Høeg has according to sources floated the idea of preventing adolescent males from obtaining COVID-19 vaccinations.

“She’s an complete true believer who starts off with her preconceived notions and reverse-engineers to accommodate the evidence in a very deceptive, dishonest way,” Dr. Howard stated.

Consolidating Power and a “Campaign of Retribution”

Høeg aligned with fellow contrarians, {like|